Ca/CaM-Stimulated and cGMP-Specific Phosphodiesterases in Vascular and Non-Vascular Tissues

  • H. S. Ahn
  • M. Foster
  • M. Cable
  • B. J. R. Pitts
  • E. J. Sybertz

Abstract

A large body of evidence indicates that guanosine 3’,5’-cyclic monophosphate (cGMP) plays an essential role in vasorelaxant actions of various agents such as atrial natriuretic factor (ANF), nitrogen oxide containing compounds (e.g., nitroprusside) and endothelium dependent vasodilators (e.g., acetylcholine) (1). These agents elevate cGMP by stimulating either soluble or particulate guanylate cyclase (1).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 78: 1–5, 1986.PubMedCrossRefGoogle Scholar
  2. 2.
    Beavo JA. Multiple isozymes of cyclic nucleotide phosphodiesterase. Adu Second Messenger Phosphoprotein Res 22: 1–38, 1988.Google Scholar
  3. 3.
    Lorenz KL, Wells JN. Potentiation of the effects of sodium nitroprusside and of isoproterenol by selective phosphodiesterase inhibitors. Mol Pharmacol 23: 424–430, 1983.PubMedGoogle Scholar
  4. 4.
    Hidaka H, Endo T. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterases—basic and potential clinical applications. Adv Cyclic Nucleotide Res 16: 245–259, 1984.Google Scholar
  5. 5.
    Lugnier C, Schoeffter P, LeBec A, Strouthou E, Stoclet JC. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 35: 1743–1751, 1986.PubMedCrossRefGoogle Scholar
  6. 6.
    Ahn HS, Crim W, Romano M, Moroney S, Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases (PDEs) of rabbit and pig aorta. Pharmacologist 29: 522, 1987.Google Scholar
  7. 7.
    Hagiware M, Endo T, Hidaka H. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol 33: 453–457, 1984.CrossRefGoogle Scholar
  8. 8.
    Bergstrand H, Kristoffersson J, Lundquist B, Schurmann A. Effects of antiallergic agents, compounds 48/80, and some reference inhibitors on the activity of partially purified human lung tissue adenosine cyclic 3’,5’-monophosphate and guanosine cyclic 3’5’monophosphate phosphodiesterases. Mol Pharmacol 13: 38–43, 1977.PubMedGoogle Scholar
  9. 9.
    Ahn HS, Crim W, Romano M, Moroney SJ, Sybertz EJ, Pitts B. Calmodulin dependent phosphodiesterase (CaM-PDE) and cyclic GMP specific PDE (cG-PDE) distribution and response to inhibitors in aorta and non-vascular tissues. Pharmacologist 30: A213, 1988.Google Scholar
  10. 10.
    Hansen RS, Beavo AJ. Differential recognition of calmodulinenzyme complexes by a conformation-specific anti-calmodulin monoclonal antibody. JBiol Chem 261: 14636–14645, 1986.Google Scholar
  11. 11.
    Ahn HS, Crim W, Romano M, Sybertz EJ, Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 38: 3331–3339, 1989.PubMedCrossRefGoogle Scholar
  12. 12.
    Ahn HS, Eardley D, Watkins R, Prioli N. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism. Biochem Pharmacol 34: 1113–1121, 1986.CrossRefGoogle Scholar
  13. 13.
    Ahn HS, Crim W, Pitts B, Sybertz EJ. Ca/CaM-stimulated and cGMP specific phosphodiesterases: tissue distribution, drug sensitivity and regulation of cGMP levels. Adv Second Messenger Phosphoprotein Res, Vol. 24, In Press, 1990.Google Scholar
  14. 14.
    Sharma RK, Wang JH. Isolation of bovine brain calmodulindependent cyclic nucleotide phosphodiesterase isozyme. Methods in Enzymology 159: 582–594, 1988.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • H. S. Ahn
    • 1
  • M. Foster
    • 1
  • M. Cable
    • 1
  • B. J. R. Pitts
    • 1
  • E. J. Sybertz
    • 1
  1. 1.Department of PharmacologySchering-Plough Research DivisionBloomfieldUSA

Personalised recommendations